714-X (PDQ®): Complementary and alternative medicine - Health Professional Information [NCI] - Summary of the Evidence for 714-X
To assist readers in evaluating the results of human/clinical studies of complementary and alternative medicine (CAM) treatments for cancer, a scoring system has been devised that allows studies of individual treatments to be ranked according to the strength of their evidence (i.e., their level of evidence). Not all studies, however, are given a level of evidence score. To be eligible, a study must:
Evaluate a therapeutic outcome(s), such as tumor response, improvement in survival, or carefully measured improvement in quality of life.
Be reported in a peer-reviewed scientific journal.
Have its clinical findings published in sufficient detail that a meaningful evaluation can be made.
Evidence from studies that do not meet these requirements is considered extremely weak. In addition to scoring individual studies, a summary of the evidence is usually made.
Standard Treatment Options for Extramedullary Plasmacytoma
Standard treatment options for extramedullary plasmacytoma include the following:
Radiation therapy to the isolated lesion with fields that cover the regional lymph nodes, if possible.[1,2]
In some cases, surgical resection may be considered, but it is usually followed by radiation therapy.
If the monoclonal (or myeloma) protein (M protein) persists or reappears, the patient may need further radiation therapy. In...
Because no study of the use of 714-X in humans has been reported in a peer-reviewed scientific journal, no level of evidence analysis is possible for this treatment. Therefore, at this time, the use of 714-X as a treatment for cancer cannot be recommended outside the context of well-designed clinical trials.
For additional information about levels of evidence analysis, refer to Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine.